Preventing and Managing Cytomegalovirus in High-Risk Hematopoietic Cell Transplantation Patients: Expert Answers to Frequently Asked Questions

In this CME-certified module, experts provide answers to common questions about best practices in the prevention and management of cytomegalovirus infection in hematopoietic cell transplantation recipients.
Roy F. Chemaly, MD
Program Director
Genovefa A. Papanicolaou, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: January 16, 2019 Expiration: January 15, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Formulate prophylactic strategies for patients at high risk for CMV infection following HCT
  • Devise management strategies for HCT patients with CMV infection based on the results of recent clinical studies
  • Provide insightful counsel to patients and colleagues regarding emerging strategies in identifying and managing patients at high risk for CMV infection post HCT


Provided by Postgraduate Institute for Medicine.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Merck & Co., Inc.

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Roy F. Chemaly, MD

Professor of Medicine
Department of Infectious Diseases, Infection Control, and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, has disclosed that he has received consulting fees from Chimerix, Clinigen, Merck, Oxford Immunotec, and Shire; fees for non-CME/CE services from Merck and Oxford Immunotec; and funds for research support from Chimerix, Merck, Novartis, Oxford Immunotec, and Shire.


Genovefa A. Papanicolaou, MD

Department of Medicine
Weill Medical College
Cornell University
Attending Physician
Clinical Trials
Infectious Disease Service
Memorial Sloan Kettering
New York, New York

Genovefa A. Papanicolaou, MD, has disclosed that she has received consulting fees from Astellas, Chimerix, Clinigen, Merck, and Siemens and funds for research support from Merck.


Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologic oncologists and other clinicians practicing within BMT centers.


The goal of this activity is to close the knowledge and practice gaps and improve clinician competence in managing CMV in patients.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 16, 2019, through January 15, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options, explore patient cases with expert recommendations for CMV prophylaxis and treatment in patients who have undergone HCT.

Roy F. Chemaly, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: February 26, 2019 Expired: February 25, 2020

How has the approval of letermovir prophylaxis altered post-HCT CMV management? Here’s my take.

Genovefa A. Papanicolaou, MD Released: January 16, 2018

In this downloadable slideset, Kathleen Mullane, DO, PharmD, provides expert perspectives on current and emerging strategies for preventing and managing CMV infection in patients undergoing bone marrow transplantation.

Released: December 13, 2017

In this CME-certified interactive presentation, Kathleen Mullane, DO, PharmD, provides expert perspectives on optimal strategies for preventing and managing CMV infection in patients undergoing bone marrow transplantation.

Kathleen Mullane, DO, PharmD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 13, 2017 Expired: December 12, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?